FibroBiologics, Inc. faces significant near-term challenges marked by a going concern warning in its April 2026 10-Q due to recurring losses and limited cash. The company continues to develop its fibroblast-based cell therapy products, primarily CYWC628 for diabetic foot ulcers, but manufacturing complexities and low yields at third-party CDMOs threaten trial timelines. Despite operational headwinds, FibroBiologics has secured new patents and is actively managing costs and financing efforts, including an ATM equity program to extend its runway. The biotech’s future hinges on resolving manufacturing issues, hitting clinical milestones, and successfully raising capital to support development and commercialization activities.